Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The scope of the trial is to assess the free progression rate at 2 months for each group of patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Oscar Lambret
• Treatments: Cyclophosphamide; Megestrol; Megestrol Acetate

Criteria

Inclusion Criteria:

• Age > or = 18

• PS-WHO < or = 1

• Histologically proven cancer

• No other therapeutic proposal

• Treatment can be orally taken

• Radiologic proof of evolutive character of the disease

• Effective contraception

Exclusion Criteria:

• Hypercalcemia ( Ca > 2.65 mmol/l)

• Breast cancer

• Thrombosis or pulmonary embolism

• Dysphagia, malabsorption

• Polynuclear neutrophil leukocytes < 1000/mm3

• Treatment with Tegretol

• Active and uncontrolled infection

• Evolutive psychiatric disease

• Pregnant or lactating woman